Multimodal Imaging Based on Pathological and Genomic Characteristics
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05196243 |
Recruitment Status :
Recruiting
First Posted : January 19, 2022
Last Update Posted : April 1, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Mitochondrial DNA Mutation Endoscopy | Other: Patients diagnosed as gastrointestinal mucosal lesions |
Study Type : | Observational |
Estimated Enrollment : | 200 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | A New Multimodal Imaging Technique Based on Pathological and Genomic Characteristics of Gastrointestinal Mucosa |
Actual Study Start Date : | March 21, 2022 |
Estimated Primary Completion Date : | June 1, 2022 |
Estimated Study Completion Date : | July 1, 2024 |

Group/Cohort | Intervention/treatment |
---|---|
Study Group
Study on the genomic and molecular pathological characteristics of gastrointestinal mucosal lesions
|
Other: Patients diagnosed as gastrointestinal mucosal lesions
Patients diagnosed as gastritis, gastric cancer, intestinal polyps and colorectal cancer |
Control Group
Study on the genomic and molecular pathological characteristics of normal gastrointestinal mucosa
|
- Single cell sequencing and identification of mitochondrial DNA variation in gastrointestinal lesions [ Time Frame: 1 month ]Single cell sequencing and identification of mitochondrial DNA mutations in gastrointestinal lesions were carried out to trace the clonal origin of cells and look for molecular markers
- To explore the multimodal imaging technique for the diagnosis of gastrointestinal mucosal lesions [ Time Frame: 1 month ]The tissue characteristics are analyzed by the full spectrum imaging device, the location, distribution and aggregation of key molecules on the cell membrane are observed by the high resolution imaging device, the imaging probe with high labeling efficiency and biosafety is developed, and the clinical application is discussed. in order to realize the information fusion of structural and functional imaging in the process of gastrointestinal tumor evolution and diagnosis and treatment.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Diagnosis or suspected diagnosis of one of the following common digestive mucosal diseases: gastritis, gastric cancer, colorectal polyps, bowel cancer
- Written informed consent
Exclusion Criteria:
- Patients with cardiovascular and cerebrovascular diseases, or patients with severe impairment of liver, kidney and hematopoietic system
- Mental patients
- Hemorrhagic diseases
- Platelet count < 50 × 10 ^ 9 / L
- Allergic constitution
- unable to tolerate or cooperate with endoscopy
- Patients with serious complications, such as intestinal obstruction, intestinal perforation, toxic colonic dilatation, colorectal cancer, etc.
- Pregnant or lactating women

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05196243
Contact: Yan Liu, MD | +8613911798288 | 13911798288@163.com | |
Contact: Liang Wu, MD | +8618110076598 | wuliangdoc@163.com |
China, Beijing | |
The First Medical Center of Chinese PLA General Hospital | Recruiting |
Beijing, Beijing, China, 100853 | |
Contact: Yan Liu +8613911798288 13911798288@163.com | |
Principal Investigator: Yan Liu |
Principal Investigator: | Yan Liu, MD | Beijing 302 Hospital |
Responsible Party: | Affiliated Hospital to Academy of Military Medical Sciences |
ClinicalTrials.gov Identifier: | NCT05196243 |
Other Study ID Numbers: |
Multi-imaging |
First Posted: | January 19, 2022 Key Record Dates |
Last Update Posted: | April 1, 2022 |
Last Verified: | March 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Mitochondrial DNA Mutation Single cell sequencing Molecular pathology multimodal imaging holography |